Fudan University: Carcinoma, Non-Small-Cell Lung trials

The registry lists 51 Carcinoma, Non-Small-Cell Lung studies with Fudan University as lead sponsor. 22 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 27No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus ChemotherapyNot yet recruitingNCT07822984Phase 2
• Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLCRecruitingNCT07801430Not applicable
• The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07780578Phase 2
• SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung CancerNot yet recruitingNCT07619911Phase 2
• A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLCNot yet recruitingNCT07418879Not applicable
• FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung CancerNot yet recruitingNCT07418866Phase 2
• Study on the Mechanism of Acquired Resistance of EntrectinibRecruitingNCT07199959
• Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI TherapyNot yet recruitingNCT07193160Phase 2
• Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon MutationsRecruitingNCT07117890Phase 2
• Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung CancerNot yet recruitingNCT07034365
• ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIsRecruitingNCT06775743Phase 2
• Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung CancerRecruitingNCT06684418
• Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cmRecruitingNCT06634979Not applicable
• AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain MetastasesRecruitingNCT06604689
• Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLCRecruitingNCT06369181
• Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line ImmunotherapyRecruitingNCT06313541Phase 2
• Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLCNot yet recruitingNCT05910034Phase 2
• Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010)RecruitingNCT05094882
• SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)RecruitingNCT04527419Not applicable
• Prospective Observation of Failure Patterns in NSCLC Treated With ICIsNot yet recruitingNCT04492969
• Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLCRecruitingNCT04136535Phase 2
• ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)RecruitingNCT03786003Not applicable
• Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung CancerCompletedNCT05212285Results posted
• Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain MetastasesActive, not recruitingNCT07491211
• Predictive Value of Exosomes in Pleural Effusion for Advanced Lung CancerActive, not recruitingNCT07262671
• Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLCCompletedNCT06613633
• Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain MetastasisCompletedNCT06501378Phase 2
• A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung CancerCompletedNCT06161935
• SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKIActive, not recruitingNCT06020066Phase 2
• PET-CT Predicting Lymph Nodes MetastasisActive, not recruitingNCT05970913
• Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)CompletedNCT05775796Phase 2
• Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)Status unknownNCT05255406Phase 2
• Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLCTerminatedNCT05176925Phase 2
• SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIsCompletedNCT04764214Phase 2
• Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line TreatmentStatus unknownNCT04706949Phase 2
• Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung CancerStatus unknownNCT04592666Phase 2
• Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung CancerStatus unknownNCT04427475Not applicable
• SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLCStatus unknownNCT04106180Phase 2
• X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesActive, not recruitingNCT03753685Phase 2
• Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? (ECTOP-1006)CompletedNCT03689439
• Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)CompletedNCT03216551
• Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLCStatus unknownNCT02037997Phase 2
• A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive BiomarkersStatus unknownNCT01860508Not applicable
• Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)CompletedNCT01833572Phase 2
• ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLCCompletedNCT01810367Phase 2
• The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung CancerCompletedNCT01797913Phase 2
• Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)CompletedNCT01687439Phase 2
• Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer PatientsStatus unknownNCT01192243Phase 2
• Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer PatientsStatus unknownNCT01192230Phase 2
• Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung CancerStatus unknownNCT00846443Phase 1
• Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based ChemotherapyStatus unknownNCT00497250Phase 1